Monitoring System For Vector-Based Influenza Vaccine

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$2,401,160.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44AI068270-03
Agency Tracking Number:
AI068270
Solicitation Year:
2008
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2007-2
Small Business Information
INDEVR, INC.
INDEVR, INC., 2100 Central Ave, Suite 106, BOULDER, CO, 80301
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
132347787
Principal Investigator
 () -
Business Contact
Phone: (303) 402-9100
Email: admin@indevr.net
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): This Phase II Advanced Technology SBIR [PA-06-134] proposal is in response to NIAID's Notice of High-Priority Influenza Research Areas [NOT-AI-05-013]. In order to provide health officials with the tools required to eff iciently combat a pandemic strain of influenza, it is essential that rapid and cost-effective methods for vaccine production be developed. The proposed instrument is specifically designed to provide a rapid count of the number of intact viruses per unit volume in liquid. While optimization of vaccine production methods is an example application for which the number of intact viruses is a valuable measurement, the time and cost savings of virus enumeration within minutes, rather than days, is anticipated t o have substantial impact on several other virus-related fields. Support for that outlook is provided by the excellent group of collaborators we have been able to assemble during the Phase I efforts, including scientists from two large vaccine manufacturer s (MedImmune and Novartis), a small cutting-edge vaccine manufacturer (Protein Sciences Corporation), a biological reagents company (Microbix Biosystems, Inc.), a diagnostics company (Quidel Corporation), and a College of Medicine (at Baylor). All Phase I objectives were achieved and in many cases exceeded. During Phase II efforts we will i) design and construct an advanced prototype Virus CounterTM and develop automated methods for instrument parameter setup; ii) evaluate instrument performance in comparis on with standard methods such as plaque assays, fluorescence focus assays, transmission electron microscopy and real-time quantitative PCR, iii) optimize the Virus CounterTM and assay for utility in vaccine production, and iv) conduct beta-site testing of the instrument. PUBLIC HEALTH RELEVANCE: In order to provide health officials with the tools required to efficiently combat a pandemic strain of influenza, it is essential that rapid and cost-effective methods for vaccine production be developed. T he proposed instrument is specifically designed to provide a rapid count of the number of intact viruses per unit volume in liquid. While optimization of vaccine production methods is an example application for which the number of intact viruses is a val uable measurement, the time and cost savings of virus enumeration within minutes, rather than days, is anticipated to have substantial impact on several other virus-related fields.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government